Table 2

Univariable and multivariable analyses for ePFS in the overall population

CharacteristicsUnivariable analysesMultivariable analyses
HR95% CIP valueHR95% CIP value
Age ≥70 years versus <70 years 1.43 0.93 to 2.18 0. 07 1.020.99 to 1.040.12
ECOG PS 1 versus 0 1.45 0.89 to 2.33 0.08 2.04 1.11 to 3.72 0.02
Synchronous versus metachronous1.310.87 to 1.980.24
Resected primary tumour versus unresected0.840.61 to 1.150.26
Left versus right primary0.890.64 to 1.260.52
Nodal involvement versus no involvement 1.55 1.08 to 2.23 0.03 1.480.91 to 2.400.12
Baseline CEA level >200 versus ≤200 ng/mL1.190.80 to 1.770.37
Number of liver metastases ≥4 versus <4 1.67 1.22 to 2.29 0.003 1.83 1.15 to 2.90 0.01
Liver metastases maximum diameter >30 versus ≤30 mm 1.35 0.96 to 1.86 0.09 1.98 1.23 to 3.20 0.005
Bilobar involvement yes versus no1.140.82 to 1.580.44
Liver involvement >6 versus ≤6 segments 1.40 0.94 to 2.09 0.06 0.690.36 to 1.330.27
RAS/BRAF mutation versus RAS/BRAF wild type1.110.82 to 1.510.67
MSI high versus MSS 2.41 0.42 to 13.88 0.03 -*-*-*
Triplet versus doublet induction1.200.89 to 1.620.22
Anti-EGFR versus anti-VEGF1.040.73 to 1.470.37
Liver secondary resection 0.39 0.26 to 0.59 < 0.001 0.37 0.21 to 0.65 < 0.001
Liver retreatments 0.27 0.19 to 0.39 < 0.001
  • *Too small sample size for multivariable model

  • †Bold values represent statistically significant values.

  • Anti-EGFR, anti-epidermal growth factor receptor; Anti-VEGF, anti-vascular endothelial growth factor receptor; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability; MSS, microstatellite stable; PS, Performance Status; ePFS, extrahepatic progression-free survival.